Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Area of Science:

• Oncology
• Molecular Biology

Background:

• Tumor angiogenesis is crucial for cancer growth, proliferation, and metastasis, particularly in non-small cell lung cancer (NSCLC).
• The vascular endothelial growth factor (VEGF) family, including VEGF-(A-D) and placenta growth factor (PIGF), are key regulators of angiogenesis.
• Current therapeutic strategies target angiogenesis by inhibiting VEGF-vascular endothelial growth factor receptor (VEGFR) interactions or downstream signaling pathways.

Purpose of the Study:

• To review the role of tumor angiogenesis in NSCLC.
• To discuss current therapeutic approaches targeting angiogenesis, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs).
• To highlight the efficacy of bevacizumab and ramucirumab in improving overall survival (OS) for NSCLC patients.

Main Methods:

• Review of scientific literature on tumor angiogenesis and its therapeutic targeting in NSCLC.
• Analysis of clinical trial data for anti-angiogenic agents like bevacizumab and ramucirumab.
• Discussion of the mechanisms of action for VEGF/VEGFR inhibitors and TKIs.

Main Results:

• Bevacizumab (anti-VEGF) and ramucirumab (anti-VEGFR) have demonstrated improved overall survival (OS) when added to standard chemotherapy in NSCLC.
• VEGF-targeted therapies represent a significant advancement in NSCLC treatment.
• TKIs can inhibit multiple pro-angiogenic and pro-proliferative pathways, including the mitogen-activated protein (MAP) kinase pathway.

Conclusions:

• Targeting tumor angiogenesis is a validated therapeutic strategy for NSCLC.
• Bevacizumab and ramucirumab have established roles in improving patient outcomes.
• Further research into novel agents and treatment combinations holds promise for enhancing therapeutic gains in NSCLC.